Teligent, Inc. (NASDAQ:TLGT) insider Stephen Richardson acquired 6,410 shares of the business’s stock in a transaction on Thursday, November 9th. The stock was acquired at an average cost of $3.13 per share, with a total value of $20,063.30. Following the acquisition, the insider now directly owns 14,744 shares in the company, valued at $46,148.72. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Shares of Teligent, Inc. (TLGT) traded up $0.15 during trading on Thursday, hitting $3.51. 838,157 shares of the stock were exchanged, compared to its average volume of 418,130. Teligent, Inc. has a 12 month low of $2.82 and a 12 month high of $9.54. The company has a quick ratio of 3.71, a current ratio of 3.28 and a debt-to-equity ratio of 2.23.

Teligent (NASDAQ:TLGT) last issued its quarterly earnings results on Monday, November 6th. The company reported ($0.08) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.01) by ($0.07). Teligent had a negative return on equity of 6.51% and a negative net margin of 16.95%. The firm had revenue of $13.65 million for the quarter, compared to the consensus estimate of $19.12 million. During the same period last year, the company posted $0.01 EPS. The business’s revenue was down 15.5% on a year-over-year basis. research analysts forecast that Teligent, Inc. will post -0.13 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This article was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/11/16/teligent-inc-tlgt-insider-purchases-20063-30-in-stock.html.

A number of analysts have issued reports on the stock. Zacks Investment Research downgraded shares of Teligent from a “hold” rating to a “strong sell” rating in a report on Saturday, November 11th. Canaccord Genuity downgraded shares of Teligent from a “buy” rating to a “hold” rating and cut their price objective for the company from $9.00 to $5.00 in a report on Tuesday, November 7th. TheStreet downgraded shares of Teligent from a “c-” rating to a “d+” rating in a report on Wednesday, November 1st. Roth Capital set a $9.00 price target on shares of Teligent and gave the stock a “buy” rating in a report on Wednesday, August 23rd. Finally, Deutsche Bank AG cut their price target on shares of Teligent from $9.00 to $8.00 and set a “hold” rating for the company in a report on Monday, August 14th. Three analysts have rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the company. Teligent currently has an average rating of “Hold” and an average target price of $7.33.

Institutional investors have recently modified their holdings of the company. Summit Creek Advisors LLC lifted its holdings in shares of Teligent by 15.6% during the 3rd quarter. Summit Creek Advisors LLC now owns 795,853 shares of the company’s stock worth $5,340,000 after acquiring an additional 107,245 shares during the period. Janus Henderson Group PLC bought a new stake in shares of Teligent during the 2nd quarter worth approximately $51,431,000. Argent Capital Management LLC bought a new stake in shares of Teligent during the 2nd quarter worth approximately $3,590,000. JPMorgan Chase & Co. lifted its holdings in shares of Teligent by 99.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 59,773 shares of the company’s stock worth $547,000 after acquiring an additional 29,816 shares during the period. Finally, RK Capital Management LLC bought a new stake in shares of Teligent during the 2nd quarter worth approximately $4,581,000. 65.85% of the stock is owned by institutional investors.

Teligent Company Profile

Teligent, Inc is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016.

Receive News & Stock Ratings for Teligent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent Inc. and related stocks with our FREE daily email newsletter.